HA
HC Advisors’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $205K | Buy |
+4,218
| New | +$205K | 0.14% | 55 |
|
|
2024
Q4 | – | Sell |
-4,319
| Closed | -$203K | – | 62 |
|
|
2024
Q3 | $203K | Buy |
4,319
+134
| +3% | +$6.3K | 0.17% | 48 |
|
|
2024
Q2 | $226K | Sell |
4,185
-280
| -6% | -$15.1K | 0.21% | 44 |
|
|
2024
Q1 | $304K | Buy |
4,465
+158
| +4% | +$10.8K | 0.15% | 74 |
|
|
2023
Q4 | $270K | Buy |
+4,307
| New | +$270K | 0.15% | 75 |
|
|
2023
Q3 | – | Sell |
-4,008
| Closed | -$225K | – | 86 |
|
|
2023
Q2 | $225K | Sell |
4,008
-671
| -14% | -$37.7K | 0.13% | 73 |
|
|
2023
Q1 | $212K | Sell |
4,679
-622
| -12% | -$28.1K | 0.13% | 76 |
|
|
2022
Q4 | $215K | Sell |
5,301
-48,643
| -90% | -$1.98M | 0.15% | 74 |
|
|
2022
Q3 | $3.53M | Buy |
53,944
+46,512
| +626% | +$3.04M | 2.43% | 12 |
|
|
2022
Q2 | $452K | Buy |
7,432
+154
| +2% | +$9.37K | 0.32% | 49 |
|
|
2022
Q1 | $457K | Sell |
7,278
-1,211
| -14% | -$76K | 0.29% | 47 |
|
|
2021
Q4 | $643K | Buy |
8,489
+2,739
| +48% | +$207K | 0.39% | 39 |
|
|
2021
Q3 | $644K | Buy |
5,750
+43
| +0.8% | +$4.82K | 0.42% | 36 |
|
|
2021
Q2 | $924K | Buy |
5,707
+1,077
| +23% | +$174K | 0.57% | 32 |
|
|
2021
Q1 | $564K | Buy |
4,630
+412
| +10% | +$50.2K | 0.36% | 39 |
|
|
2020
Q4 | $646K | Buy |
4,218
+388
| +10% | +$59.4K | 0.44% | 38 |
|
|
2020
Q3 | $320K | Buy |
3,830
+173
| +5% | +$14.5K | 0.26% | 49 |
|
|
2020
Q2 | $269K | Buy |
+3,657
| New | +$269K | 0.22% | 64 |
|